Ivan Kairatov is a leading figure in biopharmaceutical innovation, bringing years of dedicated research and development experience to the intersection of oncology and the human microbiome. As an expert who has watched the landscape of cancer treatment shift from traditional chemotherapy to the revolutionary era of immunotherapy, Kairatov possesses a unique vantage point on why some patients thrive while others do not. His work often explores how the microscopic inhabitants of our digestive tract can be harnessed to prime the immune system for battle against aggressive malignancies like melanoma. In this conversation, we explore groundbreaking research that bridges the gap between common probiotics found in fermented dairy and the molecular machinery of T-cell activation, offering a glimpse into a future where simple dietary metabolites might be the key to overcoming immunotherapy resistance.
Summarizing the core of this discussion, we delve into the high failure rates of standard immune checkpoint inhibitors and the emerging role of the gut-microbiome-immune axis. The dialogue covers the specific identification of Bifidobacterium animalis as a potent anti-tumor agent, the isolation of mannose as a critical metabolic driver, and the intricate Hippo-YAP1 signaling pathway that governs T-cell cytotoxicity. By exploring how these elements work in synergy with existing treatments, the interview outlines a roadmap for low-cost, high-impact adjuvant therapies that could redefine the standard of care for melanoma patients.
The introduction of immune checkpoint inhibitors like anti-PD-1 was a watershed moment for oncology, yet we still see a staggering number of melanoma patients who do not benefit. Why is the gut microbiome becoming the focal point for explaining these disparate outcomes?
It is a sobering reality that while immunotherapy has transformed the prognosis for many, more than half of melanoma patients fail to respond or eventually see their cancer return due to acquired resistance. When we look closely at these non-responders, we often find a distinct lack of microbial diversity and a significant reduction in beneficial bacteria, such as Bifidobacterium, within their gut ecosystems. The tumor microenvironment is not an island; it is deeply influenced by systemic signals originating from the gut-microbiome-immune axis. We have seen in previous studies that fecal microbiota transplants from responding patients can actually “flip the switch” in non-responders, restoring their sensitivity to treatment. This tells us that the microbiome isn’t just a bystander—it is a critical determinant of whether the immune system has the “fuel” and the “instructions” necessary to identify and destroy cancer cells effectively.
In the search for specific microbial allies, how did the research team narrow their focus down to Bifidobacterium animalis, and what made this particular species stand out in the laboratory?
The journey began with a rigorous screening of five different Bifidobacterium species isolated directly from healthy human stool samples, looking for the one with the most aggressive anti-cancer profile. Among those tested, Bifidobacterium animalis—a strain many of us recognize from the labels of fermented dairy products—demonstrated the most potent ability to inhibit the growth of melanoma cells in culture. The most fascinating discovery occurred when we moved to mouse models: when given orally to mice harboring B16-F10 melanoma tumors, the bacterium significantly reduced both the volume and the weight of the tumors. Interestingly, the bacteria never actually migrated to or colonized the tumor tissue itself, which was a “lightbulb moment” for the team. It proved that the anti-tumor effects were mediated entirely through secreted metabolites that travel through the bloodstream to influence the immune response from a distance.
The discovery that a simple metabolite could replicate the effects of a live probiotic is a major step forward for biopharma. Can you explain the significance of mannose in this context and how it was identified?
Identifying the “active ingredient” among the thousands of compounds secreted by bacteria is like looking for a needle in a haystack, but size fractionation and metabolomics allowed the team to isolate a small, non-protein molecule under 3 kilodaltons in size. This molecule was mannose, a simple sugar that carries profound biological implications for our immune architecture. To test its efficacy, researchers provided mice with drinking water supplemented with just 1% mannose, and the results were nothing short of remarkable. This simple intervention replicated the anti-tumor success of the live probiotic, leading to a visible surge in tumor-infiltrating CD8+ T cells. We weren’t just seeing more cells; we were seeing “smarter” cells that produced significantly higher levels of killer molecules, specifically granzyme B, interferon-gamma, and tumor necrosis factor-alpha, which are the essential tools T cells use to dismantle a tumor.
Mechanistically, how does mannose actually “unlock” the potential of these T cells, and what role does the Hippo-YAP1 pathway play in this molecular drama?
The way mannose interacts with T cells is a beautiful example of molecular precision, as it enters the CD8+ T cells through a specific gateway known as the GLUT1 glucose transporter. Once inside, it triggers the Hippo signaling pathway, which is a critical discovery because this pathway had not previously been linked to microbial metabolites in the context of cancer immunotherapy. The activation of the Hippo pathway leads to the phosphorylation and cytoplasmic retention of a transcription factor called YAP1. Under normal circumstances, YAP1 acts as a “brake” on T-cell function, moving into the nucleus to suppress their effector capabilities. By keeping YAP1 out of the nucleus, mannose effectively removes this critical brake, allowing the T cells to reach their full cytotoxic potential.
Given the challenges of bringing new therapies to market, how do you envision the translational path for Bifidobacterium animalis or mannose as an adjuvant to existing treatments?
The beauty of this discovery lies in its inherent safety and the established history of these components; Bifidobacterium animalis is already widely consumed globally and has a sterling safety record. This makes it an incredibly attractive candidate for rapid clinical translation compared to synthetic drugs that require decades of safety testing. Furthermore, oral mannose supplementation is well-tolerated in humans and offers a standardized, low-cost approach that avoids the complexities of handling live bacterial cultures. When combined with anti-PD-1 therapy in studies, the bacterium produced a synergistic effect that was substantially more effective than either treatment alone. This suggests a future where a patient’s immunotherapy regimen could be bolstered by a simple, targeted probiotic or metabolite supplement, potentially rescuing those who are currently resistant to standard care.
What is your forecast for the future of probiotic-metabolite therapies in oncology?
I believe we are entering an era where “precision probiotics” will become a standard pillar of oncological care, moving away from generic supplements toward targeted metabolites like mannose that have a clear, mechanistic roadmap. Within the next decade, I expect we will see clinical protocols that begin with a microbiome assessment, followed by the administration of specific bacterial strains or small molecules to prime the Hippo-YAP1 axis before the first dose of immunotherapy is even given. This approach will not only improve the 50% response rate we currently struggle with but will do so using safe, naturally derived substances that reduce the overall toxic burden on the patient. We are finally learning to speak the chemical language of the gut to tell our immune system exactly how to win the fight against cancer.
